All Programs

Non-Invasive Biomarkers of Metabolic Liver Disease (NIMBLE)

Biomarkers Consortium – Plasma Aβ and Phosphorylated Tau as Predictors of Amyloid and Tau Positivity in Alzheimer’s Disease

The Problem Early treatment of Alzheimer’s disease requires early diagnosis. Yet available methods to diagnose early AD are expensive or ...

Alzheimer’s Disease Neuroimaging Initiative 3 (ADNI 3)

The Problem Individuals with Alzheimer’s disease often do not show symptoms during the early stages of disease, limiting clinicians’ ab...

AMP Alzheimer’s Disease 1.0

The Accelerating Medicines Partnership® (AMP®) Program Alzheimer’s disease (AMP AD) was the first stage of a precompetitive partnership ...